Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Better understanding smoldering myeloma & improving the outcomes of patients with high-risk myeloma

Gareth Morgan • 25 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma Antibodies

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, outlines unmet needs in the field of multiple myeloma, including the need to better understand smoldering myeloma and prevent progression to multiple myeloma, as well as improving the outcomes of patients with high-risk multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gareth Morgan

2:19
How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan • 10 Dec 2023
1:48
Investigating the non-coding myeloma genome
Gareth Morgan • 10 Dec 2023
1:29
Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Gareth Morgan • 10 Dec 2023
1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals